Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 636

Results For "NAL"

6585 News Found

FDA approves Nexviazyme for late-onset Pompe disease
Drug Approval | August 09, 2021

FDA approves Nexviazyme for late-onset Pompe disease

Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells


India's doctor-population ratio to reach WHO benchmark soon: Dr Vinod Paul
Healthcare | August 09, 2021

India's doctor-population ratio to reach WHO benchmark soon: Dr Vinod Paul

By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas


Centre releases Rs. 60 crore to states seeking grants to tackle the Sickle Cell Anaemia
Policy | August 09, 2021

Centre releases Rs. 60 crore to states seeking grants to tackle the Sickle Cell Anaemia

Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease


TAKE divests stake in Navitas Life Sciences to HIG
Biotech | August 08, 2021

TAKE divests stake in Navitas Life Sciences to HIG

The transaction is expected to close in the Q4FY22


We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals
interviews | August 07, 2021

We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals

India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.


Alkem launches Ibuprofen and Famotidine tablets in US
News | August 07, 2021

Alkem launches Ibuprofen and Famotidine tablets in US

Ibuprofen and Famotidine Tablets is an AB-rated generic therapeutic equivalent version of Horizon Medicines LLC’s Duexis Tablets, 800 mg/26.6 mg


Sanofi to acquire Translate Bio
Biotech | August 07, 2021

Sanofi to acquire Translate Bio

Advances deployment of mRNA technology across vaccines and therapeutics development


Bafna Pharma posts Q1FY 21-22 net at Rs. 2.08 Cr
News | August 07, 2021

Bafna Pharma posts Q1FY 21-22 net at Rs. 2.08 Cr

This robust growth has come despite the raging pandemic for most part of the quarter


SPI Pharma partners Azelis Americas
Supply Chain | August 07, 2021

SPI Pharma partners Azelis Americas

In the agreement, Marcor, an Azelis Americas company, will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace


Stelis Biopharma appoints Mark W. Womack as CEO
People | August 07, 2021

Stelis Biopharma appoints Mark W. Womack as CEO

He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations